Gossamer Bio vs Nektar Therapeutics
Gossamer Bio and Nektar Therapeutics are similar in size: $48.5m and $55.2m of revenue in their latest fiscal years. Nektar Therapeutics grew faster (-43.9% against -57.7%). Nektar Therapeutics kept more of each dollar of sales as profit: a net margin of -297.1% against -351.5%.
| Latest fiscal year | Gossamer BioGOSS, 2025 | Nektar TherapeuticsNKTR, 2025 |
|---|---|---|
| Revenue | $48.5m | $55.2m |
| Revenue growth | -57.7% | -43.9% |
| Net income | −$170m | −$164m |
| Operating margin | -352.2% | -253.7% |
| Net margin | -351.5% | -297.1% |
| Return on equity | — | — |
| Free cash flow | −$171m | −$209m |
| Cash | $37.7m | $15.1m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | 161 | 63 |
| Market value | $4.41bn | $765m |
| Price vs our value range | — | — |
| Moat score | — | 18 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 16 sales |